Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05604105 | Oral Cancer Awareness in Egypt | not yet recruiting | — | 1,844 | Ayat Gamal-AbdelNaserOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05621291 |
| recruiting |
| N/A |
| 60 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | suspended | Phase 2 / Phase 3 | 1,122 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05768711 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)(AVENHIR) | active not recruiting | Phase 2 | 44 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05856773 | Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy(COMPRO) | recruiting | Phase 3 | 276 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05874921 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto(uTRACT) | recruiting | — | 450 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05875168 | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 590 | Daiichi SankyoINDUSTRY | 8 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05987956 | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Medicine Invention Design, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06011304 | Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer | completed | Phase 3 | 287 | HTA Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06046794 | Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients(GemSign-01) | recruiting | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | recruiting | Phase 3 | 3,680 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06098651 | A Study of DCR-STAT3 in Adults With Solid Tumors | completed | Phase 1 | 26 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | suspended | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06307496 | VIDeOS for Smoking Cessation | completed | N/A | 40 | Medical University of South CarolinaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06309225 | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly((DACHOC-E)) | recruiting | N/A | 20 | Omar MahmoudOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06325683 | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | suspended | Phase 2 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06377540 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | recruiting | Phase 2 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06406465 | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06448754 | Volrustomig Priming Regimens Exploratory Phase II Platform Study(eVOLVE-01) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT06466434 | Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma | recruiting | N/A | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06487481 | Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06494241 | Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study | active not recruiting | — | 1,000 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | recruiting | Phase 3 | 306 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498661 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)(SHIP-A-S01) | active not recruiting | N/A | 750 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06505018 | Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment(ALTERNATIVE) | terminated | N/A | 31 | UNICANCEROTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | recruiting | Phase 3 | 320 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06524583 | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour(L-UteCIN) | recruiting | Phase 2 | 198 | UNICANCEROTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06541210 | Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men(CoLLab) | recruiting | N/A | 250 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials